RNA

Avidity Biosciences, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

28.56
0.00
0.00%
Closed 16:00 08/05 EDT
OPEN
--
PREV CLOSE
26.54
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
35.00
52 WEEK LOW
23.06
MARKET CAP
941.07M
P/E (TTM)
-44.6459
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average RNA stock price target is 48.00 with a high estimate of 60.00 and a low estimate of 36.00.

EPS

RNA News

More
Avidity Biosciences Appointes Jae Kim, M.D. As Chief Medical Officer
Benzinga · 07/27 12:22
Avidity Biosciences Appoints Jae Kim, M.D. as Chief Medical Officer
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment of Jae Kim, M.D. as Chief Medical Officer. In his
PR Newswire · 07/27 12:00
Wells Fargo: These 3 ‘Strong Buy’ Stocks Are Must-Watch Names
Are the markets on the mend? If you ask Wells Fargo’s head of equity strategy Chris Harvey, the answer is yes. Citing the S&P 500’s remarkable rebound since its March low and its strong showing over the last few days, the strategist argues that there has been
TipRanks · 07/24 00:14
The Daily Biotech Pulse: Opko Wins CDC Contract, Novartis Lowers Guidance, Pieris Study Placed On Partial Clinical Hold
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20)
Benzinga · 07/21 11:59
Wells Fargo Initiates Coverage On Avidity Biosciences with Overweight Rating
Wells Fargo analyst Jim Birchenough initiates coverage on Avidity Biosciences (NASDAQ:RNA) with a Overweight rating.
Benzinga · 07/07 11:45
Credit Suisse Initiates Coverage On Avidity Biosciences with Outperform Rating, Announces Price Target of $34
Credit Suisse analyst Martin Auster initiates coverage on Avidity Biosciences (NASDAQ:RNA) with a Outperform rating and announces Price Target of $34.
Benzinga · 07/07 11:40
The Week Ahead In Biotech: Endo, Eagle Pharma FDA Decisions, ObsEva Late-Stage Readouts In Focus
Biotech stocks rebounded in the holiday-shortened week ending July 2 as investors reacted to pending clinical trial readouts and the news flow surrounding COVID-19 vaccine and treatment development. 
Benzinga · 07/06 12:56
Benzinga Pro's Top 5 Stocks To Watch For Mon., Jul. 6, 2020: REGN, CEMI, MARK, RNA, NKTX
Today's 5 Stock Ideas:  Regeneron (REGN) - Shares were up 4% to mark a new 52-week high after the company announced the start of a Phase 3 trial for a COVID-19 treatment. The prevention trial of the
Benzinga · 07/06 12:33

Industry

Pharmaceuticals
+0.34%
Pharmaceuticals & Medical Research
+0.35%

Hot Stocks

Symbol
Price
%Change

About RNA

Avidity Biosciences, Inc. is a biopharmaceutical company. The Company focuses on oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC), designed to overcome the limitations of oligonucleotide-based therapies to treat a range of serious diseases. It utilizes its AOC platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) and the precision of oligonucleotide-based therapies. The Oligonucleotide therapeutics are designed based on genomic information to specifically inhibit or modify the expression of disease-related proteins and ribonucleic acids (RNA). It is focused on muscle diseases and consists of approximately five programs. Its lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type one (DM1). It also focuses on other muscle programs focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease.
More

Webull offers kinds of Avidity Biosciences Inc stock information, including NASDAQ:RNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RNA stock methods without spending real money on the virtual paper trading platform.